

# Eileen E Parkes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6154589/publications.pdf>

Version: 2024-02-01

26  
papers

1,035  
citations

687220

13  
h-index

713332

21  
g-index

26  
all docs

26  
docs citations

26  
times ranked

1989  
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 247-258.	2.9	14
2	When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers. <i>Trends in Cancer</i> , 2022, 8, 174-189.	3.8	27
3	A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS3637-TPS3637.	0.8	1
4	NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2682-TPS2682.	0.8	1
5	Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. <i>British Journal of Cancer</i> , 2021, 124, 581-586.	2.9	9
6	Development of Immunotherapy Combination Strategies in Cancer. <i>Cancer Discovery</i> , 2021, 11, 1368-1397.	7.7	130
7	The clinical and molecular significance associated with STING signaling in breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 81.	2.3	21
8	Abstract CT217: Phase I, first-in-human trial evaluating BI 1387446 (STING agonist) alone and in combination with ezabenlimab (BI 754091; anti-PD-1) in solid tumors. <i>Cancer Research</i> , 2021, 81, CT217-CT217.	0.4	5
9	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	7.7	139
10	Alcohol intake, tobacco smoking, and esophageal adenocarcinoma survival: a molecular pathology epidemiology cohort study. <i>Cancer Causes and Control</i> , 2020, 31, 1-11.	0.8	16
11	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , 2020, 123, 1089-1100.	2.9	51
12	Review of applications of high-throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application. <i>Briefings in Bioinformatics</i> , 2019, 20, 1795-1811.	3.2	112
13	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 3484-3492.	0.8	30
14	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. <i>Journal of Oncology</i> , 2019, 2019, 1-14.	0.6	18
15	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. <i>Gut</i> , 2019, 68, 1918-1927.	6.1	18
16	Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e21045-e21045.	0.8	0
17	Make it easier for me to deliver childcare at conferences. <i>Nature</i> , 2018, 564, S89-S89.	13.7	0
18	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. <i>Journal of Oncology</i> , 2018, 2018, 1-14.	0.6	44

#	ARTICLE	IF	CITATIONS
19	Abstract 3787: Exploring the effect of chemotherapies on STING-dependent cytokine release. Cancer Research, 2018, 78, 3787-3787.	0.4	2
20	Exploration of the cGAS-STING pathway in prostate cancer.. Journal of Clinical Oncology, 2018, 36, 5075-5075.	0.8	0
21	Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer. Journal of the National Cancer Institute, 2017, 109, djw199.	3.0	338
22	PD-L1 expression and response to neo-adjuvant chemotherapy in esophageal adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 4023-4023.	0.8	1
23	Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer. Oncologist, 2016, 21, 586-593.	1.9	23
24	A BRCA1 deficient, NF $\kappa$ B driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget, 2016, 7, 19884-19896.	0.8	30
25	Turning the concept of synthetic lethality on its head. Translational Cancer Research, 2016, 5, S1145-S1148.	0.4	0
26	Clinical Tumor Staging of Adenocarcinoma of the Esophagus and Esophagogastric Junction. Journal of Clinical Oncology, 2015, 33, 1088-1088.	0.8	5